FDA delay for ph 3 trial approval, page-40

Thanks Mozz.

I have not invested in PAR in the past, but has kept an eye on it when I heard it mentioned by a doctor many years ago and did not chase it as it ran up hard.

Recently heard from it from the Collin St team in one of their presentations and piqued my interest.

Agree, the risk / reward is exceptional here, but I bought with eyes wide open that this could drop another 50%. But the runway, if all go well, will be huge.

I wish everyone luck and hope the pay off for the patience will be huge, but I think someone out there cannot wait to offload and that worries me, because they are willing to take a huuuuge loss on their sale at this all time low prices, which is not easily explained by just slow FDA progress or small changes to dosage or possibility of another CR. Also the lack of big pharma to snap this up explains a lot about the risk.

With that said, I am in and am strapped for the ride!